Title : CD13 promotes hepatocellular carcinogenesis and sorafenib resistance by activating HDAC5-LSD1-NF-κB oncogenic signaling.

Pub. Date : 2020 Dec

PMID : 33377659






7 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 CD13 promotes hepatocellular carcinogenesis and sorafenib resistance by activating HDAC5-LSD1-NF-kappaB oncogenic signaling. Sorafenib alanyl aminopeptidase, membrane Homo sapiens
2 RATIONALE: CD13 is a new marker for liver cancer stem cells (CSCs) that contributes to sorafenib resistance in hepatocellular carcinoma (HCC). Sorafenib alanyl aminopeptidase, membrane Homo sapiens
3 However, the underlying mechanism of CD13 in HCC sorafenib resistance remains enigmatic. Sorafenib alanyl aminopeptidase, membrane Homo sapiens
4 Functionally, CD13 promoted HCC proliferation, invasion, cell cycle progression as well as sorafenib resistance. Sorafenib alanyl aminopeptidase, membrane Homo sapiens
5 A CD13 inhibitor ubenimex in combination with sorafenib, suppressed the tumor growth and attenuated the resistance of HCC cells toward sorafenib in patient-derived xenograft models. Sorafenib alanyl aminopeptidase, membrane Homo sapiens
6 CONCLUSIONS: CD13 promotes HCC progression and induces sorafenib resistance, mainly via interacting with HDAC5 to prevent the degradation of p65 and activate NF-kB signaling pathway. Sorafenib alanyl aminopeptidase, membrane Homo sapiens
7 CD13 is a prognostic indicator for HCC patients underwent curative resection as well as a predictor of response to treatment with sorafenib. Sorafenib alanyl aminopeptidase, membrane Homo sapiens